Schlieren, Zürich, Switzerland and New York, USA · 19 November 2021
Rejuveron Life Sciences AG, a Zürich-based biotechnology company developing technologies for healthy aging, has announced the appointment of Bob Silverman as Chief Business Officer (CBO). Based in the USA, Mr Silverman will also be responsible for growing the company’s presence from its new offices in New York.
Mr Silverman brings more than two decades’ experience in business development and licensing, chiefly gained at Roche and most recently with Alloy Therapeutics. His expertise in dealmaking spans the areas of venture capital, IP, enabling technologies and early- to clinical-stage assets.
Rejuveron has incorporated a US subsidiary and moved into new offices at BioLabs-NYU Langone, 180 Varick Street NYC, NY. The company is expanding its NY based team and is recruiting for an innovation scout and a head of US investor relations.
Commenting on his appointment, Bob Silverman, CBO Rejuveron Life Sciences, said: “Rejuveron is an exciting company with a big mission: supporting pioneers in the field of aging research to transform scientific discoveries into therapies that will help people to live healthier, longer lives. Our goal is to expand the human health span, enabling a higher quality of life by reducing the burden of age-related diseases. I’m thrilled to be making a contribution towards this goal.”
During a recent interview for New York BIO’s Virtual Breakfast Series, Mr Silverman, said “Expanding Rejuveron’s footprint in the USA from a new base in Manhattan will give us access to some of the country’s best talent and innovation.”
Welcoming him to the team, Rejuveron’s CEO, Mattias Steger, Ph.D., MBA said: “Bob and I met during our time working together at Roche; I was always impressed by his tenacity, integrity and knowledge of drug discovery and development. I am delighted that Bob has joined the Rejuveron team to accelerate further our business development through licensing, acquisition and partnering, lead our expansion in the US, and help make therapies happen.”
About Rejuveron
Rejuveron is a clinical-stage biotechnology company creating therapies to improve healthy aging. Its experienced drug discovery and development team applies a deep understanding of the biology of aging, alongside technological advances in biopharmaceutical R&D, to progress a new generation of medicines that will help people to age better and live longer.
Through its programs, each uniquely focused on preventing, repairing, or reversing the hallmarks of aging, Rejuveron is advancing a therapeutic pipeline that ranges from drug discovery to the clinic. Rejuveron’s business model is to create or acquire innovative programs, each being held within a wholly owned or majority-owned company.
The current portfolio is diversified across modalities, stages, as well as aging hallmarks, and includes a revolutionary small molecule approach to regenerate endogenous stem cell, currently in a Phase 1/2a in the USA in retinitis pigmentosa patients; a novel drug combination therapy for sarcopenia in a Phase 1b human trial.
Rejuveron has headquarters and state-of-the-art laboratories in Switzerland’s biotech hub in Bio-Technopark Schlieren, Zürich with Abu Dhabi operations in the process of being set up. Its current portfolio includes: Endogena Therapeutics (Switzerland, USA & Canada), Rejuveron Senescence Therapeutics (Switzerland & Spain), Rejuveron Vascular Therapeutics (Switzerland), Rejuveron Telomere Therapeutics (Switzerland), Rejuvenate BioMed (Belgium) and Boost Neuroscience (US).
Co-founded in 2019 by entrepreneurial scientist, Matthias Steger, and visionary investor, Christian Angermayer, Rejuveron has state-of-the-art incubator laboratory facilities and offices at its headquarters in Zürich’s Bio-Technopark (Switzerland) as well as program teams located in the USA, Canada, Spain and Belgium.
